PUBLICATIONS

Anthony Faber’s Selected Bibliography 

• Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.
  Floros KV, Fairchild CK, Li J, Zhang K, Roberts JL, Kurupi R, Hu B, Kraskauskiene V, Hosseini N, Shen S, Inge MM, Smith-Fry K, Li L, Sotiriou A, Dalton KM, Jose A, Abdelfadiel EI, Xing Y, Hill RD, Slaughter JM, Shende M, Lorenz MR, Hinojosa MR, Belvin BR, Lai Z, Boikos SA, Stamatouli AM, Lewis JP, Manjili MH, Valerie K, Li R, Banito A, Poklepovic A, Koblinski JE, Siggers T, Dozmorov MG, Jones KB, Radhakrishnan SK, Faber AC.bioRxiv [Preprint]. 2024 Apr 27:2024.04.25.591023. doi: 10.1101/2024.04.25.591023.PMID: 38712286  Preprint.
• High-Dose Acetaminophen with Concurrent CYP2E1 Inhibition Has Profound Anticancer Activity without Liver Toxicity.
  Bryan A, Pingali P, Faber A, Landry J, Akakpo JY, Jaeschke H, Li H, Lee WS, May L, Patel B, Neuwelt A.J Pharmacol Exp Ther. 2024 Jan 2;388(1):209-217. doi: 10.1124/jpet.123.001772.PMID: 37918853
• Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment.
  Neely V, Manchikalapudi A, Nguyen K, Dalton K, Hu B, Koblinski JE, Faber AC, Deb S, Harada H.Int J Mol Sci. 2023 Aug 23;24(17):13082. doi: 10.3390/ijms241713082.PMID: 37685889
• Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.
  Jacob S, Turner TH, Cai J, Floros KV, Yu AK, Coon CM, Khatri R, Alzubi MA, Jakubik CT, Bouck YM, Puchalapalli M, Shende M, Dozmorov MG, Boikos SA, Hu B, Harrell JC, Benes CH, Koblinski JE, Costa C, Faber AC.PNAS Nexus. 2022 Oct 11;1(5):pgac232. doi: 10.1093/pnasnexus/pgac232. eCollection 2022 Nov.PMID: 36712364
• Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
  Kurupi R, Floros KV, Jacob S, Chawla AT, Cai J, Hu B, Puchalapalli M, Coon CM, Khatri R, Crowther GS, Egan RK, Murchie E, Greninger P, Dalton KM, Ghotra MS, Boikos SA, Koblinski JE, Harada H, Sun Y, Morgan IM, Basu D, Dozmorov MG, Benes CH, Faber AC.Cancer Res Commun. 2022 Sep;2(9):1061-1074. doi: 10.1158/2767-9764.crc-21-0137. Epub 2022 Sep 26.PMID: 36506869
• High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
  Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC.Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095.PMID: 35905710
• MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma.
  Floros KV, Chawla AT, Johnson-Berro MO, Khatri R, Stamatouli AM, Boikos SA, Dozmorov MG, Cowart LA, Faber AC.Cell Stress. 2022 Jan 17;6(2):21-29. doi: 10.15698/cst2022.02.264. eCollection 2022 Feb.PMID: 35174317
• Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
  Ahmadinejad F, Bos T, Hu B, Britt E, Koblinski J, Souers AJ, Leverson JD, Faber AC, Gewirtz DA, Harada H.Mol Pharmacol. 2022 Mar;101(3):168-180. doi: 10.1124/molpharm.121.000354. Epub 2021 Dec 14.PMID: 34907000
• Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
  Carpenter V, Saleh T, Min Lee S, Murray G, Reed J, Souers A, Faber AC, Harada H, Gewirtz DA.Biochem Pharmacol. 2021 Nov;193:114765. doi: 10.1016/j.bcp.2021.114765. Epub 2021 Sep 15.PMID: 34536356
• Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
  Heisey DAR, Jacob S, Lochmann TL, Kurupi R, Ghotra MS, Calbert ML, Shende M, Maves YK, Koblinski JE, Dozmorov MG, Boikos SA, Benes CH, Faber AC.Mol Cancer Ther. 2021 Oct;20(10):1868-1879. doi: 10.1158/1535-7163.MCT-20-0489. Epub 2021 Jul 26.PMID: 34315769
• Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma.
  Dalton KM, Krytska K, Lochmann TL, Sano R, Casey C, D’Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, Jacob S, Kurupi R, Hu B, Dozmorov M, Greninger P, Souers AJ, Benes CH, Mossé YP, Faber AC.Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4.PMID: 34088831
• Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA.
  Fairchild CK Jr, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA.Cancers (Basel). 2021 May 12;13(10):2310. doi: 10.3390/cancers13102310.PMID: 34065859
• Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
  Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, McClanaghan J, Murchie E, Egan RK, Greninger P, Dozmorov M, Ramamoorthy S, Puchalapalli M, Hu B, Shock L, Koblinski J, Glod J, Boikos SA, Benes CH, Faber AC.Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2009620118. doi: 10.1073/pnas.2009620118.PMID: 33762304
• Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
  Floros KV, Jacob S, Kurupi R, Fairchild CK, Hu B, Puchalapalli M, E Koblinski J, Dozmorov MG, Boikos SA, Scaltriti M, Faber AC.Cell Death Dis. 2021 Feb 15;12(2):179. doi: 10.1038/s41419-021-03457-6.PMID: 33589591
• MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis.
  Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, Coon CM, Powell KM, Belvin BR, Hu B, Puchalapalli M, Ramamoorthy S, Swift K, Lewis JP, Dozmorov MG, Glod J, Koblinski JE, Boikos SA, Faber AC.Cancer Res. 2021 Apr 1;81(7):1896-1908. doi: 10.1158/0008-5472.CAN-20-1641. Epub 2021 Jan 22.PMID: 33483374
• Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X_L -BAX interaction.
  Saleh T, Carpenter VJ, Tyutyunyk-Massey L, Murray G, Leverson JD, Souers AJ, Alotaibi MR, Faber AC, Reed J, Harada H, Gewirtz DA.Mol Oncol. 2020 Oct;14(10):2504-2519. doi: 10.1002/1878-0261.12761. Epub 2020 Aug 5.PMID: 32652830
• Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?
  Floros KV, Hata AN, Faber AC.Cancer Res. 2020 Jan 1;80(1):25-26. doi: 10.1158/0008-5472.CAN-19-3405.PMID: 31900282
• Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers.
  Ebi H, Boikos S, Faber AC.J Thorac Dis. 2019 Sep;11(Suppl 15):S1844-S1846. doi: 10.21037/jtd.2019.08.122.PMID: 31632765  No abstract available.
• Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death.
  Song KA, Faber AC.J Thorac Dis. 2019 Jun;11(6):E82-E85. doi: 10.21037/jtd.2019.06.11.PMID: 31372302  No abstract available.
• Paragangliomas in Carney-Stratakis Syndrome.
  Khurana A, Mei L, Faber AC, Smith SC, Boikos SA.Horm Metab Res. 2019 Jul;51(7):437-442. doi: 10.1055/a-0918-8340. Epub 2019 Jun 7.PMID: 31174229 Review.